AMD and DR drug market to reach $6.25bn by 2015
There is a strong and growing market for drugs to treat the eye diseases AMD and DR, analysts say
The market for age-related macular degeneration (AMD) and diabetic retinopathy (DR) drugs is set to reach $6.25 billion by 2015, new research suggests.
Business information provider Visiongain has published its latest projections for the market for the period 2013-2023.
According to the company, the market has been boosted by the recent launch of Regeneron's Eylea in 2011, which is now competing with Roche/Novartis' Lucentis and Roche's Avastin for wet AMD market share.
Visiongain also noted that the R&D pipeline for eye drugs is currently strong, with new anti-vascular endothelial growth factor (VEGF) drugs and PDGF-B blockers on the horizon.
James Evans, a pharmaceutical industry analyst at Visiongain, said: "The DR market has been galvanised by the approval of Lucentis and Alimera's Iluvien in 2012, and there's plenty of room for growth in that segment."
He cited research indicating that more than 100 million people around the world have diabetic retinopathy, providing a "huge patient population" for pharmaceutical companies in the field to target.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News From Pharma to Table? Direct-to-consumer pharma sales and price cuts ramp up in US
The pharmaceutical industry is witnessing a seismic shift as major companies embrace direct-to-consumer sales models and announce significant price reductions across the United States, responding to mounting pressure from the Trump administration to ta... -
News A Day in the Life of a Director of Business Development
In this Day in the Life of interview, Thomas Hauser, Director of Business Development at Tjoapack. Thomas has spent nearly 30 years in the pharmaceutical industry and describes how he still finds curiosity and excitement in the bigger picture of global... -
.png)
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective.